Health Economics›Non-small cell lung cancer›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer · 59 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 14 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) and Ipilimumab Variant #01	—	R 788 798	21d	—	~13.4 mo	~6	~R 3 160 481 PFS proxy · indirect	1
Carboplatin and nab-Paclitaxel (CnP), Durvalumab, Tremelimumab Variant #01 Partial	—	R 312 869	28d	6.2 mo	14.0 mo	5	R 1 119 776 PFS proxy	3
Carboplatin and nab-Paclitaxel (CnP) and Durvalumab Variant #01	—	R 312 869	28d	5.5 mo	13.3 mo	4	R 988 075 PFS proxy	3
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	8.4 mo	22.1 mo	2	R 573 911 PFS proxy	9
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	11.7 mo	2	R 263 402 PFS proxy	1
Cisplatin and Gemcitabine (GC) and Cetuximab Variant #01	—	R 83 408	21d	—	—	~6	~R 252 425 indirect	—
Cisplatin and Vinorelbine (CVb) and Cetuximab Variant #01	—	R 79 307	21d	—	11.3 mo	6	R 263 250 PFS proxy	1
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	~10.7 mo	—	~2	~R 105 582 PFS proxy · indirect	6
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #01	—	R 48 987	28d	—	10.9 mo	12	R 473 840 PFS proxy	1
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 41 178	21d	—	—	4	R 164 713 PFS proxy	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	20.2 mo	2	R 62 509 PFS proxy	2
GIP Variant #01	—	R 18 587	21d	—	—	~4	~R 74 348 indirect	—
Carboplatin and Pemetrexed Variant #01	—	R 14 563	21d	8.6 mo	13.3 mo	6	R 87 376 PFS proxy	6
Cisplatin and Pemetrexed Variant #01	—	R 13 666	21d	8.6 mo	13.1 mo	7	R 94 340 PFS proxy	5
CCI Variant #01	—	R 11 415	28d	—	—	~2	~R 22 830 indirect	—
Ifosfamide and Gemcitabine Variant #01	—	R 11 259	28d	—	—	~2	~R 22 518 indirect	—
Cisplatin and Vinblastine Variant #01	—	R 9 253	84d	—	13.7 mo	3	R 13 318 PFS proxy	—
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
VeIP Variant #01	—	R 8 275	21d	—	—	~5	~R 41 376 indirect	—
MIC Variant #01	—	R 8 193	21d	—	7.6 mo	4	R 32 771 PFS proxy	1
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	—	9.4 mo	9	R 56 391 PFS proxy	—
Carboplatin and Gemcitabine (GCb) and Paclitaxel Variant #01	—	R 6 151	21d	—	10.8 mo	7	R 43 055 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	4.2 mo	8.2 mo	6	R 33 004 PFS proxy	2
Gemcitabine and Paclitaxel Variant #01	—	R 5 224	21d	—	9.8 mo	6	R 31 344 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	6.0 mo	10.0 mo	2	R 8 829 PFS proxy	7
Gemcitabine and Vinorelbine Variant #01	—	R 4 259	21d	—	6.7 mo	6	R 25 555 PFS proxy	2
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	6.0 mo	10.4 mo	6	R 23 595 PFS proxy	14
MVP (Vinblastine) Variant #01	—	R 3 554	28d	—	—	~4	~R 12 400 indirect	—
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	—	13.0 mo	3	R 9 556 PFS proxy	2
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	8.4 mo	2	R 5 843 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Cemiplimab Variant #01 Partial	—	R 2 807	21d	—	21.5 mo	36	R 11 226 PFS proxy	2
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	10.6 mo	11	R 29 874 PFS proxy	1
Docetaxel and Vinorelbine Variant #01	—	R 2 634	14d	—	—	~2	~R 5 268 indirect	—
MVP (Vindesine) Variant #01 Partial	—	R 2 551	28d	—	—	~6	~R 11 674 indirect	—
Cisplatin and Vinorelbine (CVb) Variant #01	—	R 2 418	21d	—	9.8 mo	10	R 24 184 PFS proxy	6
Carboplatin and Etoposide (CE) Variant #01	—	R 2 301	28d	~4.6 mo	~10.6 mo	~7	~R 16 108 PFS proxy · indirect	17
Carboplatin and Vinorelbine Variant #01	—	R 1 985	21d	—	6.7 mo	3	R 5 956 PFS proxy	1
Cisplatin and Paclitaxel (TP) and Cemiplimab Variant #01 Partial	—	R 1 910	21d	—	21.5 mo	36	R 7 640 PFS proxy	2
Cisplatin and Etoposide (EP) Variant #22	—	R 1 819	21d	—	7.6 mo	4	R 7 277 PFS proxy	—
Cisplatin and Irinotecan (IC) Variant #01	—	R 1 795	21d	—	13.9 mo	5	R 8 977 PFS proxy	4
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	6.2 mo	7	R 11 705 PFS proxy	4
Carboplatin and Cisplatin Variant #01	—	R 1 391	28d	—	—	~2	~R 2 782 indirect	—
Carboplatin and S-1 Variant #01 Partial	—	R 1 338	21d	—	15.2 mo	4	R 5 351 PFS proxy	1
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	5.3 mo	9.5 mo	7	R 9 204 PFS proxy	4
CISCA Variant #02	—	R 1 258	21d	—	—	~6	~R 7 550 indirect	—
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	5.3 mo	10.3 mo	18	R 18 445 PFS proxy	32
FULV Variant #29	—	R 806	14d	~5.6 mo	~13.1 mo	~5	~R 4 028 PFS proxy · indirect	15
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	6.8 mo	7	R 5 141 PFS proxy	2
CAMP Variant #01 Partial	—	R 711	28d	—	—	~2	~R 1 422 indirect	—
MACC Variant #01 Partial	—	R 605	21d	—	—	~2	~R 1 209 indirect	—
Cisplatin and Vindesine Variant #01 Partial	—	R 588	84d	—	—	~2	~R 1 177 PFS proxy · indirect	1
Cisplatin monotherapy Variant #01	—	R 588	21d	—	8.6 mo	2	R 1 177 PFS proxy	1
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	6.2 mo	12	R 5 490 PFS proxy	3
Cisplatin and S-1 Variant #01 Partial	—	R 441	28d	—	16.1 mo	8	R 3 530 PFS proxy	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	4.2 mo	—	2	—	1
Vindesine monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Placebo Partial	—	—	—	—	3.6 mo	—	—	1
Cemiplimab monotherapy Variant #01 Partial	—	—	21d	10.3 mo	26.1 mo	48	—	5
Best supportive care Partial	—	—	—	—	4.8 mo	—	—	1

59 of 59 regimens shown